Identification

Name
Tetryzoline
Accession Number
DB06764
Type
Small Molecule
Groups
Approved
Description

Tetryzoline (also known as Tetrahydrozoline), a derivative of imidazoline, is found in over-the-counter eye drops and nasal sprays. Other derivatives include naphazoline, oxymetazoline, and xylometazoline. Johnson and Johnson manufactures tetryzoline eye drops under the brand Visine ®.

Structure
Thumb
Synonyms
  • (RS)-2-(1,2,3,4-tetrahydronaphthalen-1-yl)-4,5-dihydro-1H-imidazole
  • Tetrahydrozoline
  • Tetrizolina
  • Tetryzolin
  • Tétryzoline
  • Tetryzolinum
Product Ingredients
IngredientUNIICASInChI Key
Tetrahydrozoline hydrochloride0YZT43HS7D522-48-5BJORNXNYWNIWEY-UHFFFAOYSA-N
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
TyzineSolution1 mg/mLNasalPharma Derm, A Division Of Fougera Pharmaceuticals Inc.1979-11-302017-01-31Us
Tyzine PediatricSolution.5 mg/mLNasalPharma Derm, A Division Of Fougera Pharmaceuticals Inc.1979-11-302017-01-31Us
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Assured Original Relief EyeSolution.5 mg/mLOphthalmicGreenbrier International, Inc.2013-02-28Not applicableUs
CAREALL Eyedrops OriginalSolution / drops.05 mg/mLOphthalmicNew World Imports2014-06-01Not applicableUs
Circle K Eye Drops Redness RelieverSolution / drops.5 mg/mLTopicalLil' Drug Store Products, Inc.2016-05-04Not applicableUs
CVS Redness Relief OriginalSolution / drops.5 mg/mLOphthalmicCVS Health2014-03-06Not applicableUs
Dg Health OriginalSolution.5 mg/mLOphthalmicHANLIM PHARM. CO., LTD.2010-08-12Not applicableUs
DG Health Sterile Redness ReliefSolution.5 mg/mLOphthalmicDolgencorp2014-11-25Not applicableUs
Equate Eye DropsLiquid.5 mg/mLOphthalmicPrestige Brands Holdings, Inc.2013-02-11Not applicableUs
Equate Eye DropsLiquid.5 mg/mLOphthalmicPrestige Brands Holdings, Inc.2013-02-11Not applicableUs
Eye DropsSolution / drops.05 g/100mLOphthalmicNorth Safety Products2018-07-04Not applicableUs
Eye DropsSolution / drops.05 %OphthalmicRivex Ophthalmics Inc.1997-08-112000-08-03Canada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
8-symptom ReliefTetrahydrozoline hydrochloride (0.05 %) + Zinc sulfate (0.25 %)SolutionOphthalmicTeva2016-07-22Not applicableCanada
Advance Relief Eye DropsTetrahydrozoline hydrochloride (50 mg/100mL) + Polyethylene glycol 400 (1000 mg/100mL) + Povidone (1000 mg/100mL)Solution / dropsOphthalmicWin Co Foods, Llc,2015-01-09Not applicableUs
Advanced reliefTetrahydrozoline hydrochloride (.5 mg/mL) + Polyethylene glycol 400 (10 mg/mL) + Povidone (10 mg/mL)LiquidOphthalmicKareway Product, Inc.2011-08-11Not applicableUs
Advanced reliefTetrahydrozoline hydrochloride (.5 mg/mL) + Polyethylene glycol 400 (10 mg/mL) + Povidone (10 mg/mL)LiquidOphthalmicAmerican Sales Company2011-09-07Not applicableUs
Advanced reliefTetrahydrozoline hydrochloride (.5 mg/mL) + Polyethylene glycol 400 (10 mg/mL) + Povidone (10 mg/mL)LiquidOphthalmicSamchundang Pharm. Co., Ltd.2010-08-29Not applicableUs
Advanced Relief Eye DropsTetrahydrozoline hydrochloride (0.05 %) + Polyethylene glycol 400 (1 %) + Povidone (1 %)SolutionOphthalmicTeva2010-08-30Not applicableCanada
Advanced Relief Eye DropsTetrahydrozoline hydrochloride (0.05 %) + Polyethylene glycol 400 (1 %) + Povidone (1 %)SolutionOphthalmicKc Pharmaceuticals, Inc.Not applicableNot applicableCanada
Allergy Eye DropsTetrahydrozoline hydrochloride (0.05 %) + Zinc sulfate (0.25 %)SolutionOphthalmicTeva2007-05-23Not applicableCanada
Allergy Eye DropsTetrahydrozoline hydrochloride (0.05 %) + Zinc sulfate (0.25 %)SolutionOphthalmicKc Pharmaceuticals, Inc.Not applicableNot applicableCanada
Allergy Eye DropsTetrahydrozoline hydrochloride (0.05 %) + Zinc sulfate (0.25 %)Solution / dropsOphthalmicAlcon, Inc.2005-06-242009-04-24Canada
Categories
UNII
S9U025Y077
CAS number
84-22-0
Weight
Average: 200.285
Monoisotopic: 200.131348523
Chemical Formula
C13H16N2
InChI Key
BYJAVTDNIXVSPW-UHFFFAOYSA-N
InChI
InChI=1S/C13H16N2/c1-2-6-11-10(4-1)5-3-7-12(11)13-14-8-9-15-13/h1-2,4,6,12H,3,5,7-9H2,(H,14,15)
IUPAC Name
2-(1,2,3,4-tetrahydronaphthalen-1-yl)-4,5-dihydro-1H-imidazole
SMILES
C1CN=C(N1)C1CCCC2=CC=CC=C12

Pharmacology

Indication

For temporary relief of discomfort and redness of the eye due to minor eye irritations.

Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action

Tetryzoline is an alpha-adrenergic agonist. Its primary action is the constriction of conjunctival blood vessels, which serves to decrease eye redness caused by minor ocular irritants.

TargetActionsOrganism
AAlpha-1A adrenergic receptor
agonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Reports of prolonged cardiovascular effects after unintentional ingestion of tetrahydrozoline are noted in the literature.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Tetryzoline.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Tetryzoline.Approved, Investigational
AcepromazineAcepromazine may decrease the vasoconstricting activities of Tetryzoline.Approved, Vet Approved
AlfuzosinAlfuzosin may decrease the vasoconstricting activities of Tetryzoline.Approved, Investigational
AmineptineAmineptine may increase the vasopressor activities of Tetryzoline.Illicit, Withdrawn
AmitriptylineAmitriptyline may increase the vasopressor activities of Tetryzoline.Approved
AmitriptylinoxideAmitriptylinoxide may increase the vasopressor activities of Tetryzoline.Approved, Investigational
AmoxapineAmoxapine may increase the vasopressor activities of Tetryzoline.Approved
AmphetamineAmphetamine may increase the hypertensive activities of Tetryzoline.Approved, Illicit, Investigational
AripiprazoleAripiprazole may decrease the vasoconstricting activities of Tetryzoline.Approved, Investigational
AsenapineAsenapine may decrease the vasoconstricting activities of Tetryzoline.Approved
AtomoxetineAtomoxetine may increase the hypertensive activities of Tetryzoline.Approved
BenmoxinBenmoxin may increase the hypertensive activities of Tetryzoline.Withdrawn
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Tetryzoline.Approved, Illicit
Benzylpenicilloyl PolylysineTetryzoline may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BevantololBevantolol may decrease the vasoconstricting activities of Tetryzoline.Approved
BrexpiprazoleBrexpiprazole may decrease the vasoconstricting activities of Tetryzoline.Approved, Investigational
BrofaromineBrofaromine may increase the hypertensive activities of Tetryzoline.Experimental
BromocriptineBromocriptine may increase the hypertensive and vasoconstricting activities of Tetryzoline.Approved, Investigational
BucindololThe risk or severity of adverse effects can be increased when Tetryzoline is combined with Bucindolol.Investigational
BunazosinBunazosin may decrease the vasoconstricting activities of Tetryzoline.Investigational
ButriptylineButriptyline may increase the vasopressor activities of Tetryzoline.Approved
CabergolineCabergoline may increase the hypertensive and vasoconstricting activities of Tetryzoline.Approved
CaffeineThe risk or severity of adverse effects can be increased when Tetryzoline is combined with Caffeine.Approved
CaroxazoneCaroxazone may increase the hypertensive activities of Tetryzoline.Withdrawn
CarvedilolThe therapeutic efficacy of Tetryzoline can be decreased when used in combination with Carvedilol.Approved, Investigational
CeliprololThe risk or severity of adverse effects can be increased when Celiprolol is combined with Tetryzoline.Approved, Investigational
ChlorphentermineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Tetryzoline.Illicit, Withdrawn
ChlorpromazineChlorpromazine may decrease the vasoconstricting activities of Tetryzoline.Approved, Investigational, Vet Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Clenbuterol is combined with Tetryzoline.Approved, Investigational, Vet Approved
ClomipramineClomipramine may increase the vasopressor activities of Tetryzoline.Approved, Investigational, Vet Approved
ClozapineClozapine may decrease the vasoconstricting activities of Tetryzoline.Approved
CyclobenzaprineCyclobenzaprine may increase the vasopressor activities of Tetryzoline.Approved
DapiprazoleDapiprazole may decrease the vasoconstricting activities of Tetryzoline.Approved
DesipramineDesipramine may increase the vasopressor activities of Tetryzoline.Approved, Investigational
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Tetryzoline.Approved, Investigational
DextroamphetamineDextroamphetamine may decrease the vasoconstricting activities of Tetryzoline.Approved, Illicit
DibenzepinDibenzepin may increase the vasopressor activities of Tetryzoline.Experimental
DiethylpropionThe risk or severity of adverse effects can be increased when Tetryzoline is combined with Diethylpropion.Approved, Illicit
DihydroergocornineDihydroergocornine may increase the hypertensive activities of Tetryzoline.Approved
DihydroergocristineDihydroergocristine may increase the hypertensive activities of Tetryzoline.Approved, Experimental
DihydroergocryptineDihydroergocryptine may increase the hypertensive activities of Tetryzoline.Experimental
DihydroergotamineDihydroergotamine may increase the hypertensive and vasoconstricting activities of Tetryzoline.Approved, Investigational
DimetacrineDimetacrine may increase the vasopressor activities of Tetryzoline.Approved, Withdrawn
DobutamineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Tetryzoline.Approved
DopamineThe risk or severity of adverse effects can be increased when Dopamine is combined with Tetryzoline.Approved
DosulepinDosulepin may increase the vasopressor activities of Tetryzoline.Approved
DoxazosinThe therapeutic efficacy of Tetryzoline can be decreased when used in combination with Doxazosin.Approved
DoxepinDoxepin may increase the vasopressor activities of Tetryzoline.Approved, Investigational
DoxofyllineThe risk or severity of adverse effects can be increased when Tetryzoline is combined with Doxofylline.Approved, Investigational
DronabinolDronabinol may increase the tachycardic activities of Tetryzoline.Approved, Illicit
DronedaroneDronedarone may decrease the vasoconstricting activities of Tetryzoline.Approved
DroperidolDroperidol may decrease the vasoconstricting activities of Tetryzoline.Approved, Vet Approved
DuloxetineDuloxetine may increase the tachycardic activities of Tetryzoline.Approved
EpanololThe risk or severity of adverse effects can be increased when Tetryzoline is combined with Epanolol.Experimental
EphedrineThe risk or severity of adverse effects can be increased when Ephedrine is combined with Tetryzoline.Approved
EpinephrineThe risk or severity of adverse effects can be increased when Epinephrine is combined with Tetryzoline.Approved, Vet Approved
Ergoloid mesylateErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Tetryzoline.Approved
ErgonovineErgonovine may increase the hypertensive and vasoconstricting activities of Tetryzoline.Approved
ErgotamineErgotamine may increase the hypertensive and vasoconstricting activities of Tetryzoline.Approved
EscitalopramEscitalopram may decrease the vasoconstricting activities of Tetryzoline.Approved, Investigational
EtilefrineThe risk or severity of adverse effects can be increased when Tetryzoline is combined with Etilefrine.Withdrawn
FenoterolThe risk or severity of adverse effects can be increased when Fenoterol is combined with Tetryzoline.Approved, Investigational
FenozoloneThe risk or severity of adverse effects can be increased when Tetryzoline is combined with Fenozolone.Experimental
FentanylThe therapeutic efficacy of Fentanyl can be decreased when used in combination with Tetryzoline.Approved, Illicit, Investigational, Vet Approved
FlupentixolFlupentixol may decrease the vasoconstricting activities of Tetryzoline.Approved, Investigational, Withdrawn
FurazolidoneFurazolidone may increase the hypertensive activities of Tetryzoline.Approved, Investigational, Vet Approved
GanciclovirThe risk or severity of adverse effects can be increased when Tetryzoline is combined with Ganciclovir.Approved, Investigational
HarmalineHarmaline may increase the hypertensive activities of Tetryzoline.Experimental
HyaluronidaseHyaluronidase may increase the vasoconstricting activities of Tetryzoline.Approved, Investigational
HydracarbazineHydracarbazine may increase the hypertensive activities of Tetryzoline.Experimental
HydroxyamphetamineThe risk or severity of adverse effects can be increased when Tetryzoline is combined with Hydroxyamphetamine.Approved
IloperidoneIloperidone may decrease the vasoconstricting activities of Tetryzoline.Approved
ImipramineImipramine may increase the vasopressor activities of Tetryzoline.Approved
IndoraminIndoramin may decrease the vasoconstricting activities of Tetryzoline.Withdrawn
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Tetryzoline.Approved, Investigational
IprindoleIprindole may increase the vasopressor activities of Tetryzoline.Experimental
IproclozideIproclozide may increase the hypertensive activities of Tetryzoline.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of Tetryzoline.Withdrawn
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Tetryzoline.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Tetryzoline.Approved, Investigational
IsoxsuprineThe risk or severity of adverse effects can be increased when Tetryzoline is combined with Isoxsuprine.Approved, Withdrawn
LabetalolThe therapeutic efficacy of Tetryzoline can be decreased when used in combination with Labetalol.Approved
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Tetryzoline.Approved, Investigational
LinezolidLinezolid may increase the hypertensive activities of Tetryzoline.Approved, Investigational
LisdexamfetamineLisdexamfetamine may decrease the vasoconstricting activities of Tetryzoline.Approved, Investigational
LisurideLisuride may increase the hypertensive activities of Tetryzoline.Approved, Investigational
LofepramineLofepramine may increase the vasopressor activities of Tetryzoline.Experimental
Lysergic Acid DiethylamideLysergic Acid Diethylamide may increase the hypertensive activities of Tetryzoline.Illicit, Investigational, Withdrawn
MebanazineMebanazine may increase the hypertensive activities of Tetryzoline.Withdrawn
MefenorexThe risk or severity of adverse effects can be increased when Tetryzoline is combined with Mefenorex.Experimental
MelitracenMelitracen may increase the vasopressor activities of Tetryzoline.Experimental, Investigational
MephentermineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Tetryzoline.Approved
MetaraminolThe risk or severity of adverse effects can be increased when Metaraminol is combined with Tetryzoline.Approved, Investigational
MetergolineMetergoline may increase the hypertensive activities of Tetryzoline.Experimental
MethamphetamineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Tetryzoline.Approved, Illicit
MethotrimeprazineMethotrimeprazine may decrease the vasoconstricting activities of Tetryzoline.Approved, Investigational
MethoxamineThe risk or severity of adverse effects can be increased when Methoxamine is combined with Tetryzoline.Approved, Investigational
Methylene blueMethylene blue may increase the hypertensive activities of Tetryzoline.Approved, Investigational
MethylergometrineMethylergometrine may increase the hypertensive and vasoconstricting activities of Tetryzoline.Approved
MethysergideMethysergide may increase the hypertensive activities of Tetryzoline.Approved
MetoprololThe therapeutic efficacy of Tetryzoline can be decreased when used in combination with Metoprolol.Approved, Investigational
MidodrineThe risk or severity of adverse effects can be increased when Midodrine is combined with Tetryzoline.Approved
MilnacipranMilnacipran may increase the tachycardic activities of Tetryzoline.Approved, Investigational
MinaprineMinaprine may increase the hypertensive activities of Tetryzoline.Approved
MoclobemideMoclobemide may increase the hypertensive activities of Tetryzoline.Approved, Investigational
NabiloneNabilone may increase the tachycardic activities of Tetryzoline.Approved, Investigational
NefazodoneNefazodone may decrease the vasoconstricting activities of Tetryzoline.Approved, Withdrawn
NialamideNialamide may increase the hypertensive activities of Tetryzoline.Withdrawn
NicardipineThe therapeutic efficacy of Tetryzoline can be decreased when used in combination with Nicardipine.Approved, Investigational
NicergolineNicergoline may increase the hypertensive activities of Tetryzoline.Approved, Investigational
NiguldipineThe therapeutic efficacy of Tetryzoline can be decreased when used in combination with Niguldipine.Experimental
NorepinephrineThe risk or severity of adverse effects can be increased when Norepinephrine is combined with Tetryzoline.Approved
NortriptylineNortriptyline may increase the vasopressor activities of Tetryzoline.Approved
NylidrinThe risk or severity of adverse effects can be increased when Nylidrin is combined with Tetryzoline.Approved
OctamoxinOctamoxin may increase the hypertensive activities of Tetryzoline.Withdrawn
OlanzapineOlanzapine may decrease the vasoconstricting activities of Tetryzoline.Approved, Investigational
OpipramolOpipramol may increase the vasopressor activities of Tetryzoline.Investigational
OrciprenalineThe risk or severity of adverse effects can be increased when Orciprenaline is combined with Tetryzoline.Approved
OxymetazolineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Tetryzoline.Approved, Investigational
PaliperidonePaliperidone may decrease the vasoconstricting activities of Tetryzoline.Approved
PargylinePargyline may increase the hypertensive activities of Tetryzoline.Approved
Patent BlueThe therapeutic efficacy of Tetryzoline can be decreased when used in combination with Patent Blue.Approved
PergolidePergolide may increase the hypertensive activities of Tetryzoline.Approved, Investigational, Vet Approved, Withdrawn
PhenelzinePhenelzine may increase the hypertensive activities of Tetryzoline.Approved
PheniprazinePheniprazine may increase the hypertensive activities of Tetryzoline.Withdrawn
PhenmetrazineThe risk or severity of adverse effects can be increased when Phenmetrazine is combined with Tetryzoline.Approved, Illicit
PhenoxybenzaminePhenoxybenzamine may decrease the vasoconstricting activities of Tetryzoline.Approved
PhenoxypropazinePhenoxypropazine may increase the hypertensive activities of Tetryzoline.Withdrawn
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Tetryzoline.Approved, Illicit
PhentolaminePhentolamine may decrease the vasoconstricting activities of Tetryzoline.Approved
PhenylephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Tetryzoline.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Tetryzoline.Approved, Vet Approved, Withdrawn
PirlindolePirlindole may increase the hypertensive activities of Tetryzoline.Approved
PivhydrazinePivhydrazine may increase the hypertensive activities of Tetryzoline.Withdrawn
PizotifenPizotifen may decrease the vasoconstricting activities of Tetryzoline.Approved
PrazosinPrazosin may decrease the vasoconstricting activities of Tetryzoline.Approved
PrenalterolThe risk or severity of adverse effects can be increased when Tetryzoline is combined with Prenalterol.Experimental
ProcaineProcaine may increase the hypertensive activities of Tetryzoline.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the hypertensive activities of Tetryzoline.Approved, Investigational
ProcaterolThe risk or severity of adverse effects can be increased when Procaterol is combined with Tetryzoline.Approved, Investigational
PromazinePromazine may decrease the vasoconstricting activities of Tetryzoline.Approved, Vet Approved
PropafenoneThe therapeutic efficacy of Tetryzoline can be decreased when used in combination with Propafenone.Approved
PropericiazinePropericiazine may decrease the vasoconstricting activities of Tetryzoline.Approved, Investigational
PropiomazinePropiomazine may decrease the vasoconstricting activities of Tetryzoline.Approved
PropiverinePropiverine may decrease the vasoconstricting activities of Tetryzoline.Approved, Investigational
PropranololThe therapeutic efficacy of Tetryzoline can be decreased when used in combination with Propranolol.Approved, Investigational
ProtriptylineProtriptyline may increase the vasopressor activities of Tetryzoline.Approved
PseudoephedrineThe risk or severity of adverse effects can be increased when Tetryzoline is combined with Pseudoephedrine.Approved
QuetiapineThe therapeutic efficacy of Tetryzoline can be decreased when used in combination with Quetiapine.Approved
QuinidineQuinidine may decrease the vasoconstricting activities of Tetryzoline.Approved, Investigational
RacepinephrineThe risk or severity of adverse effects can be increased when Tetryzoline is combined with Racepinephrine.Approved
RasagilineRasagiline may increase the hypertensive activities of Tetryzoline.Approved
RisperidoneRisperidone may decrease the vasoconstricting activities of Tetryzoline.Approved, Investigational
RitodrineThe risk or severity of adverse effects can be increased when Ritodrine is combined with Tetryzoline.Approved, Investigational
SafrazineSafrazine may increase the hypertensive activities of Tetryzoline.Withdrawn
SelegilineSelegiline may increase the hypertensive activities of Tetryzoline.Approved, Investigational, Vet Approved
SilodosinSilodosin may decrease the vasoconstricting activities of Tetryzoline.Approved
SpironolactoneThe therapeutic efficacy of Tetryzoline can be decreased when used in combination with Spironolactone.Approved
SynephrineThe risk or severity of adverse effects can be increased when Tetryzoline is combined with Synephrine.Experimental
TamsulosinTamsulosin may decrease the vasoconstricting activities of Tetryzoline.Approved, Investigational
Tedizolid phosphateTedizolid Phosphate may increase the hypertensive activities of Tetryzoline.Approved
TerazosinTerazosin may decrease the vasoconstricting activities of Tetryzoline.Approved
TerbutalineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Tetryzoline.Approved
TergurideTerguride may increase the hypertensive activities of Tetryzoline.Experimental
ThioproperazineThioproperazine may decrease the vasoconstricting activities of Tetryzoline.Approved
ThioridazineThioridazine may decrease the vasoconstricting activities of Tetryzoline.Approved, Withdrawn
TianeptineTianeptine may increase the vasopressor activities of Tetryzoline.Approved, Investigational
TolazolineTolazoline may decrease the vasoconstricting activities of Tetryzoline.Approved, Vet Approved
ToloxatoneToloxatone may increase the hypertensive activities of Tetryzoline.Approved
TramazolineThe risk or severity of adverse effects can be increased when Tetryzoline is combined with Tramazoline.Investigational
TranylcypromineTranylcypromine may increase the hypertensive activities of Tetryzoline.Approved, Investigational
TrazodoneTrazodone may decrease the vasoconstricting activities of Tetryzoline.Approved, Investigational
TretoquinolThe risk or severity of adverse effects can be increased when Tetryzoline is combined with Tretoquinol.Experimental
TrifluoperazineTrifluoperazine may decrease the vasoconstricting activities of Tetryzoline.Approved, Investigational
TrimazosinTrimazosin may decrease the vasoconstricting activities of Tetryzoline.Experimental
TrimipramineTrimipramine may increase the vasopressor activities of Tetryzoline.Approved
TyramineThe risk or severity of adverse effects can be increased when Tetryzoline is combined with Tyramine.Investigational, Nutraceutical
UrapidilUrapidil may decrease the vasoconstricting activities of Tetryzoline.Investigational
ValaciclovirThe risk or severity of adverse effects can be increased when Tetryzoline is combined with Valaciclovir.Approved, Investigational
VenlafaxineVenlafaxine may increase the tachycardic activities of Tetryzoline.Approved
VerapamilThe therapeutic efficacy of Tetryzoline can be decreased when used in combination with Verapamil.Approved
WIN 55212-2The risk or severity of Tachycardia can be increased when WIN 55212-2 is combined with Tetryzoline.Experimental
ZiprasidoneZiprasidone may decrease the vasoconstricting activities of Tetryzoline.Approved
ZuclopenthixolZuclopenthixol may decrease the vasoconstricting activities of Tetryzoline.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Carr ME, Engebretsen KM, Ho B, Anderson CP: Tetrahydrozoline (Visine(R)) concentrations in serum and urine during therapeutic ocular dosing: a necessary first step in determining an overdose. Clin Toxicol (Phila). 2011 Nov;49(9):810-4. doi: 10.3109/15563650.2011.615064. Epub 2011 Oct 5. [PubMed:21972870]
  2. Spiller H, Griffith J: Prolonged cardiovascular effects after unintentional ingestion of tetrahydrozoline. Clin Toxicol (Phila). 2008 Feb;46(2):171-2. doi: 10.1080/15563650701258070. [PubMed:18259967]
External Links
KEGG Drug
D08578
KEGG Compound
C07912
PubChem Compound
5419
PubChem Substance
310264881
ChemSpider
5226
BindingDB
96559
ChEBI
28674
ChEMBL
CHEMBL1266
Drugs.com
Drugs.com Drug Page
Wikipedia
Tetrahydrozoline
ATC Codes
S01GA02 — TetryzolineS01GA52 — Tetryzoline, combinationsR01AA06 — TetryzolineR01AB03 — Tetryzoline
AHFS Codes
  • 52:32.00 — Vasoconstrictors
FDA label
Download (134 KB)
MSDS
Download (60.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2, 3TerminatedPreventionPenetrating Keratoplasty1
Not AvailableRecruitingTreatmentAtropine Allergy / Myopia, Progressive1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
SolutionOphthalmic
Solution / dropsOphthalmic.05 mg/mL
Solution / dropsTopical.5 mg/mL
LiquidOphthalmic
Solution / dropsOphthalmic.05 g/100mL
Solution / dropsOphthalmic.5 mg
Solution / dropsIntraocular.05 g/100mL
Solution / dropsIntraocular
Solution / dropsOphthalmic
LiquidTopical.5 mg/mL
Solution / dropsOphthalmic.5 mg/mg
SolutionOphthalmic.5 mg/mL
SolutionOphthalmic0.05 %
SolutionOphthalmic0.5 mg
Solution / dropsOphthalmic.05 %
LiquidOphthalmic.5 mg/mL
Solution / dropsOphthalmic.05 mg/mg
Solution / dropsOphthalmic.5 mg/10mg
LiquidOphthalmic.05 g/100mL
SolutionNasal1 mg/mL
SolutionNasal.5 mg/mL
Kit
Solution / dropsOphthalmic0.05 %
Solution / dropsOphthalmic.5 mg/mL
Solution / dropsOphthalmic.05 mg/10mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)256-257Analytical Specifications – TETRAHYDROZOLINE. 2010 National Medical Services, Inc.
Predicted Properties
PropertyValueSource
Water Solubility0.239 mg/mLALOGPS
logP3.11ALOGPS
logP2.24ChemAxon
logS-2.9ALOGPS
pKa (Strongest Basic)10.17ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area24.39 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity61.48 m3·mol-1ChemAxon
Polarizability22.93 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0udi-0390000000-8abf8ed167116d96cf2d

Taxonomy

Description
This compound belongs to the class of organic compounds known as tetralins. These are polycyclic aromatic compounds containing a tetralin moiety, which consists of a benzene fused to a cyclohexane.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Tetralins
Sub Class
Not Available
Direct Parent
Tetralins
Alternative Parents
Imidolactams / Imidazolines / Propargyl-type 1,3-dipolar organic compounds / Carboximidamides / Carboxamidines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Tetralin / Imidolactam / 2-imidazoline / Azacycle / Organoheterocyclic compound / Organic 1,3-dipolar compound / Propargyl-type 1,3-dipolar organic compound / Carboximidamide / Carboxylic acid amidine / Amidine
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
carboxamidine, imidazolines (CHEBI:28674)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Spiller H, Griffith J: Prolonged cardiovascular effects after unintentional ingestion of tetrahydrozoline. Clin Toxicol (Phila). 2008 Feb;46(2):171-2. doi: 10.1080/15563650701258070. [PubMed:18259967]

Drug created on September 14, 2010 10:21 / Updated on August 15, 2018 09:54